Search

A recent study conducted at West China Second University Hospital focused on the effectiveness of epicutaneous immunotherapy (EPIT) in managing food allergies in children. The meta-analysis of seven randomized controlled trials involving 1141 participants showed that EPIT significantly facilitated desensitization in patients with food allergies, particularly peanut allergies. However, EPIT was associated with an increased risk of treatment-related adverse events. The research concluded that while EPIT may induce desensitization in children with peanut allergies, it also carries a higher risk of adverse events. [Extracted from the article]

A recent study conducted in Pamplona, Spain, focused on the clinical management of plant food allergies in patients sensitized to lipid transfer proteins (LTP). The research highlighted the wide clinical variability among patients and the lack of clear diagnostic and therapeutic guidelines, leading to heterogeneous practices among allergists. The study emphasized the need for increased evidence to reduce this variability in the clinical management of LTP allergy. The findings were published in the Journal of Investigational Allergology and Clinical Immunology and were peer-reviewed. [Extracted from the article]

Researchers from Padang, Indonesia, have highlighted the increasing prevalence of food allergies globally, emphasizing the importance of accurate diagnosis and effective treatment. The study explores the role of immunotherapy in managing food allergies, discussing various administration routes and newer formulation approaches to improve safety and efficacy. The principle of immunotherapy involves gradually exposing individuals to specific allergens to build tolerance, offering a promising approach to address food allergy cases. [Extracted from the article]

The article from Immunotherapy Weekly discusses research findings on allergies, specifically focusing on soy allergies. The study highlights the importance of developing specific monoclonal antibodies to detect individual soy allergens in food samples, aiming to improve allergen detection methodologies and address challenges faced by individuals with soy allergies. This advancement is seen as a significant step towards enhancing precision in allergy diagnosis and may have broader applications for other food allergenic sources. The research was conducted by the Institute of Bioanalytics and Agro-Metabolomics and is published in the Journal of Food Quality. [Extracted from the article]

A recent study conducted at the University of Cincinnati examined the differences in familiarity with oral immunotherapy (OIT) among caregivers of White, Black, and Hispanic children with food allergies. The research found that caregivers from minoritized racial and ethnic groups were less familiar with OIT, even after adjusting for household income. This study sheds light on potential racial and ethnic disparities in access to OIT as a treatment option for food allergies. [Extracted from the article]

Researchers at the University of Massachusetts in Worcester have published a report on T follicular helper (Tfh) cells and their role in directing antibody production to food antigens, which can lead to food allergies. The study highlights the different phenotypes of Tfh cells that induce antibodies to food and the immune responses that can occur at various barrier sites in the body. The research, supported by grants from the Smith Family Award and Charles H. Hood Foundation Child Health Research Award, aims to advance our understanding of how Tfh cells promote antibodies to food and potential future discoveries in this area. [Extracted from the article]

A recent study conducted at the Universite du Quebec a Chicoutimi focused on food allergies, specifically IgE-mediated food allergies, and the use of oral immunotherapy (OIT) for managing them. The research aimed to better understand the biological mechanisms underlying food allergies and OIT prognosis by recruiting children with food allergies and non-allergic siblings. The study concluded that this interdisciplinary initiative could make food allergy care more accessible and provide better treatment options through a deeper understanding of the biological nature of food allergies and OIT. [Extracted from the article]

A recent study from the University of Parma explores the relationship between asthma and food allergies in children, highlighting shared risk factors and the impact of both conditions on respiratory health. The research emphasizes the importance of understanding this interplay for developing effective treatment strategies, including the potential use of biological therapies like Omalizumab. The study suggests that managing food allergies in children with asthma involves dietary avoidance, self-injectable adrenaline for severe reactions, and potentially oral immunotherapy. For more information, the full article can be accessed for free at the Children journal website. [Extracted from the article]

A recent study conducted at the Institute of Allergy focused on the impact of oral immunotherapy (OIT) on adults with food allergies. The research found that OIT significantly improved the quality of life for adults with food allergies, with patients experiencing better scores in various aspects such as allergen avoidance, emotional impact, and risk of allergen exposure. This study highlights the potential benefits of OIT for adults with food allergies and supports its use in this population. [Extracted from the article]

Researchers from Sant'Andrea University Hospital in Rome, Italy, have conducted a comprehensive review on the use of probiotics and other adjuvants in allergen-specific immunotherapy for food allergies. The study highlights the potential of manipulating the microbiome to enhance oral tolerance in food allergy treatment, focusing on allergen-specific immunotherapy (FA-AIT) and the use of probiotics, particularly strains of Lactobacillus. Clinical trials combining probiotics with FA-AIT have shown improved desensitization rates and immune tolerance in food-allergic patients, suggesting that integrating probiotics and other adjuvants into FA-AIT protocols could enhance the safety and efficacy of treatment. [Extracted from the article]

A study conducted by the University of Missouri - Kansas City highlights the lack of racial and ethnic diversity in food allergy immunotherapy clinical trials. The researchers found that the majority of participants in these trials were White, while Black and Hispanic patients were underrepresented. This lack of diversity limits the applicability of trial results and treatments to the broader population and contributes to health care inequities. The study emphasizes the importance of addressing this disparity to improve the usefulness of future clinical trial data and alleviate public health inequities. [Extracted from the article]

A study conducted at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, evaluated the cost-effectiveness of omalizumab as a treatment for food allergies. The study used a 15-year horizon and Monte Carlo simulation to assess health and economic outcomes. The results showed that at current pricing, omalizumab is not cost-effective, but it could be if the retail price is lower or if it creates significant health utility shifts in the family and patient. The study suggests that further research is needed to explore the potential benefits of omalizumab for food allergy treatment. [Extracted from the article]

A report from King's College London discusses recent findings on innate lymphoid cells (ILCs) in immunoglobulin E (IgE)-mediated food allergy. The research highlights the importance of ILCs in the immune mechanisms of food allergy and their potential role in modulating immune responses. The study suggests that better understanding of these pathways could lead to novel therapeutic targets and treatments for food allergy. The research is peer-reviewed and can be found in the journal Current Opinion in Allergy and Clinical Immunology. [Extracted from the article]

A recent study conducted by researchers at Tokyo University of Science has explored the potential of percutaneous immunotherapy as a treatment for food allergies. The study focused on the use of PLGA-PEG-PLGA nanoparticles to deliver an antigen model protein derived from egg white. The researchers found that the nanoparticles facilitated stable delivery deep into the skin, resulting in increased serum IgG1 antibody production and decreased serum IgE production in mice. These findings suggest that the combination of PLGA-PEG-PLGA nanoparticles and iontophoresis could be an effective percutaneous immunotherapy for food allergies. [Extracted from the article]

A recent report from the University of Rochester highlights common targets for the treatment and prevention of atopic dermatitis (AD) and IgE-mediated food allergy (IgE-FA). The research emphasizes the shared pathophysiological features of these conditions, including epithelial barrier dysfunction, immune abnormalities, and microbial dysbiosis. The study suggests that targeted biologic therapies, such as dupilumab and omalizumab, may reduce symptom burden in pediatric populations. However, further research is needed to determine the potential for disease remission and prevention. The report calls for consistent age stratification and standardized regimens in future studies to improve interpretation and treatment outcomes. [Extracted from the article]

A recent study conducted in Rome, Italy, explored the effects of dupilumab, a monoclonal antibody used to treat atopic dermatitis (AD), on patients with AD and food allergies. The study found that treatment with dupilumab resulted in a significant decrease in specific IgE levels and molecular components associated with food allergies. The researchers suggest that modulating type 2 immunity may reduce IgE-mediated responses and alleviate allergic symptoms in patients with multiple sensitivities. Further randomized controlled trials are needed to confirm the potential of dupilumab in treating IgE-mediated food allergies. [Extracted from the article]

A recent study from the University of Colorado School of Medicine explores the evolution of food allergy prevention over the past three decades. The study identifies five distinct epochs that have shaped food allergy prevention, with each epoch characterized by different approaches and recommendations. The research concludes that an early introduction approach to food allergy prevention is both cost-effective and beneficial to patient quality of life. The study provides valuable insights into the changing landscape of food allergy prevention and highlights the importance of humility in adapting prevention strategies. [Extracted from the article]

A clinical trial, NCT06554691, is currently recruiting participants to study the immunological basis of tree nut and peanut allergies and the effectiveness of oral immunotherapy (OIT) as a treatment option. Peanut and tree nut allergies are common in children and can be life-threatening. The study aims to identify immune markers that correlate with clinical reactivity and changes that correlate with immunotherapy outcomes. Participants will gradually increase their intake of the allergen over 26 weeks, followed by a maintenance phase. Blood and stool samples will be collected throughout the study, and personal data will be protected. The trial is open to individuals aged 2 to 70 years and is expected to be completed by December 2026. [Extracted from the article]

A new report from researchers at Northwell Health in New Hyde Park, New York, explores the relationship between the gut microbiome and food allergies in children. The study found that dysbiosis, or an imbalance in gut bacteria, may precede the onset of food allergies. The researchers compared the microbiomes of children with milk, egg, or peanut allergies to those without allergies, stratified by age. They found that dysbiosis was more prominent in older children with peanut allergies, suggesting that therapeutic interventions should be considered at a younger age. This research has been peer-reviewed and published in the Annals of Allergy Asthma & Immunology. [Extracted from the article]

A recent study published in Immunotherapy Weekly discusses the current state of research on food allergies. The study highlights the significant increase in the prevalence of food allergies worldwide and the changes in management strategies. The researchers emphasize the importance of early introduction of common allergenic foods and the development of immunotherapy-based treatments. The study also explores the environmental and genetic factors contributing to the development of food allergies. Overall, the research aims to improve clinical care for patients with food allergies and enhance our understanding of the immunological mechanisms involved. [Extracted from the article]

A patent application has been submitted for a new method of treating food allergies using medical foods. The inventor's goal is to provide a more accessible and cost-effective alternative to pharmaceutical agents. The method involves gradually increasing the consumption of allergenic food products under medical supervision to develop tolerance. Initial results have been promising, with a high percentage of patients achieving the target dose and passing oral challenges. The method aims to desensitize patients to specific food allergies over a period of several weeks. [Extracted from the article]

A patent has been issued for an anti-IgE antibody therapy for multiple food allergies. The patent, assigned to Genentech Inc., describes a method of treating individuals with food allergies by administering a pharmaceutical composition containing omalizumab, an anti-IgE antibody. The therapy aims to reduce or prevent allergic reactions to food allergens in patients who are allergic to those allergens. The patent provides specific dosing instructions based on body weight and total serum IgE level. This therapy addresses an unmet need for improved treatments for food allergies, particularly for patients allergic to multiple foods. [Extracted from the article]

A recent study from Louisiana State University provides an overview of the history and current state of food allergies. The research highlights the challenges faced in recognizing and diagnosing food allergies, as well as the milestones in diagnosis, treatment, prevention, and research. The study emphasizes the importance of strict avoidance of allergenic foods and discusses the potential of oral and epicutaneous immunotherapy as treatment options. The research concludes that while progress has been made, there is still much to learn and improve upon in the field of food allergies. [Extracted from the article]

A recent study from Stanford University explores the potential of emerging biologics in managing food allergies. The study highlights the efficacy of anti-immunoglobulin E monoclonal antibodies in desensitization and safety improvement during oral immunotherapy. Next-generation antibodies such as ligelizumab and UB-221 show enhanced potency and unique mechanisms for food allergy treatment. Dupilumab, targeting IL-4 receptor alpha, presents potential benefits in decreasing allergen-specific IgE and modifying the atopic march. The research emphasizes the importance of tailoring therapeutic approaches based on shared decision-making and patient preferences. The study concludes that biologics offer allergists an expanded toolbox for personalized food allergy management. [Extracted from the article]

A patent application has been submitted for the invention of anti-Ara H 2 antibodies, which could potentially be used to treat peanut allergies. Peanut allergies are a common and serious condition, and the rates of food allergies are on the rise. The antibodies described in the patent application have the ability to bind to the peanut allergen and prevent allergic reactions by blocking the release of inflammatory substances. This invention could offer a new treatment option for individuals with peanut allergies and help prevent severe reactions. The patent application also includes information on how these antibodies can be used to assess the treatment response of individuals with peanut allergies to peanut exposure. [Extracted from the article]

A recent study conducted at Humanitas University in Milan, Italy, explores new treatments for food allergies, specifically focusing on oral immunotherapy (OIT) and biologics. The study suggests that these treatments, either alone or in combination, may have a role in modifying the disease and improving patient outcomes. The FDA has recently approved omalizumab as a treatment for food allergy, and other biologics are currently being evaluated. The research highlights the shift towards personalized medicine and the need for further studies to assess the efficacy and safety of these therapies. [Extracted from the article]

A recent study conducted at the University of Michigan has provided new information about food allergies. The research focused on allergen-encapsulating nanoparticles and their ability to suppress pathogenic Th2 cells, which are a major driver of food allergies. The nanoparticles were found to provoke the accumulation of regulatory T cells in the small intestine, reducing the frequency and activity of allergic effector cells. This study suggests that allergen-specific immunotherapies, such as the use of nanoparticles, could be effective in attenuating allergic responses. [Extracted from the article]

A patent application has been submitted for methods of making and evaluating allergenic tree nut compositions. The application addresses the growing prevalence of tree nut allergies and the difficulties of strict avoidance diets. It suggests oral immunotherapy as a potential treatment and outlines a process for assessing the pharmaceutical suitability of mixed tree nut powder compositions. The aim is to develop a treatment that enables individuals to tolerate accidental exposure to tree nuts and achieve a sustained unresponsiveness. The patent application details methods for evaluating and producing mixed tree nut powder compositions for pharmaceutical use, including mixing different nut flours with acceptable excipients and using liquid chromatography to determine the ratios of the nut flours. The composition is considered suitable if the ratios fall within predetermined thresholds. The application also covers methods for roasting tree nuts, creating pharmaceutical powder compositions, and packaging the final products. [Extracted from the article]

A recent report from Massachusetts General Hospital highlights the variability in food allergy thresholds among individuals. The study found that the dose of allergens needed to trigger an allergic reaction can vary significantly among people with food allergies. Factors such as IgE concentration, diversity, and function, as well as pathogenic effector TH2 cells, contribute to this variation. Understanding a patient's threshold level could help in determining appropriate treatment options, such as oral immunotherapy or the use of biologics. The study also suggests that precautionary allergen labeling on food products may cause confusion and unnecessary avoidance of certain foods. [Extracted from the article]

A recent study conducted by researchers at Johns Hopkins University highlights the increasing prevalence of food allergies and the impact they have on individuals' quality of life, nutrition, and social activities. Traditionally, food allergy treatment has focused on allergen avoidance and emergency medications. However, recent advancements in food allergy treatment, such as oral immunotherapy, offer promising alternatives. These newer approaches aim to provide safer and more effective treatment options for the millions of individuals affected by food allergies. The research has been peer-reviewed and published in The Journal of Allergy and Clinical Immunology In Practice. [Extracted from the article]

A recent report from the Murdoch Children's Research Institute in Melbourne, Australia discusses the advances in understanding the transcriptional pathways associated with outcomes following Oral Immunotherapy (OIT) for food allergies. The review highlights the use of single-cell sequencing technology to study the transcriptional landscape and summarizes the current understanding of gene expression changes during OIT. The research identifies T helper 2A cells as a cell type that correlates with disease activity and is modified by treatment. It also suggests potential mechanisms, such as T cell anergy and Type 1 interferon pathways, that support the redirection of the immune response away from allergy towards remission. However, further studies are needed to fully understand the immune mechanisms and optimize treatments for patients. [Extracted from the article]

A study conducted by researchers at Baylor University College of Medicine in Houston, Texas, explores the multifaceted approach of food allergy (FA) advocacy, research, and education. The study emphasizes the importance of addressing disparities in socioeconomic status, food security, quality of life, and the overall burden of the disease. The researchers highlight the need for advocacy initiatives to drive policy changes, raise public awareness, and direct research funding towards reducing disparities. They also stress the significance of comprehensive research that prioritizes equity and inclusivity in order to reshape the landscape of FA care and improve health care access and outcomes. [Extracted from the article]

A recent study conducted at the Chinese University of Hong Kong explored options for treating food allergies. The researchers noted that food allergies are common, affecting up to 8% of children and 10% of adults in the United States. Currently, the only advice given to patients is to avoid the allergenic foods and use rescue treatment if accidental exposure occurs. The study also mentioned that various forms of immunotherapy have been investigated, but adverse reactions, including anaphylaxis, were found to be common. The researchers concluded that patients with severe food allergies, especially those allergic to multiple foods, should carefully consider their treatment options. [Extracted from the article]

A recent study from Emory University in Atlanta, Georgia, explores current and future treatment options for IgE-mediated food allergies. The study highlights major developments in allergen-specific and allergen-non-specific treatment options, including the availability of the first FDA-approved peanut oral immunotherapy (OIT) product. However, challenges such as adverse events, frequent office visits, and cost remain with OIT. The researchers emphasize the need for further work to establish treatment protocols that minimize adverse events, identify patient priorities, and unify outcome measures. [Extracted from the article]

A study conducted by researchers at Huazhong University of Science and Technology in Wuhan, China, explores the use of low-dose oral immunotherapy (OIT) and low-dose OIT with hypoallergenic foods for the management of food allergies. The research aims to understand the mechanisms and effectiveness of these approaches in inducing oral tolerance with fewer adverse effects. The study examines the efficacy, safety, and immunological parameters of low-dose OIT and provides insights into its therapeutic application for individuals with food allergies. Further information on this research can be obtained from the Department of Allergy at Tongji Hospital, Huazhong University of Science and Technology. [Extracted from the article]

A recent analysis of published studies has found that food allergies have a greater negative impact on the quality of life of females compared to males. The analysis, which included 34 studies, revealed that women and parents of girls reported a greater impact on health-related quality of life due to food allergies. Additionally, evidence suggests that male children may experience more improvements in quality of life following immunotherapy for food allergies compared to female children. The researchers emphasize the importance of considering gender when caring for individuals with food allergies and making policy decisions. [Extracted from the article]

A recent report discusses the findings of a study on hyper-IgE syndrome, a condition characterized by severe eczema and other symptoms. The study focuses on a six-year-old girl with the condition who had difficulty controlling her eczema with topical treatments. After being diagnosed with DOCK8 deficiency, she was treated with Dupilumab, which resulted in the complete resolution of her eczema and warts. The study suggests that Dupilumab can be used to reduce inflammation and infections in patients with DOCK8 deficiency while they await a curative treatment. [Extracted from the article]

New research from the University Hospital St. Justine in Montreal, Canada, explores the efficacy and tolerance of two alternative treatments for food allergies: epicutaneous (EPIT) and sublingual (SLIT) immunotherapies. These treatments, which expose patients to smaller amounts of allergen compared to oral immunotherapy (OIT), have a lower risk of anaphylaxis. While EPIT and SLIT may have a lower ability to increase the tolerance threshold compared to OIT, they show promise in adjusting allergen-specific immune responses and disease progression, particularly in children aged 1-4. These treatments could be considered for patients who are ineligible, have failed, or refused OIT, or as a first-line treatment in cases of primary prevention failure in early childhood. [Extracted from the article]

A recent clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) found that a monoclonal antibody treatment called omalizumab significantly increased the amount of common foods that food-allergic children and adolescents could consume without experiencing an allergic reaction. The trial, called OUtMATCH, is assessing the efficacy of omalizumab in reducing the likelihood of reactions to small amounts of food allergens. The trial's independent Data and Safety Monitoring Board (DSMB) found that participants who received omalizumab injections could consume higher doses of peanut, egg, milk, and cashew without allergic reactions compared to those who received placebo injections. The trial has received support from Genentech and Novartis Pharmaceuticals Corporation, and the FDA is reviewing a supplemental biologics license application for omalizumab for food allergy based on the trial's interim analysis. [Extracted from the article]

A patent has been issued for a method of primary prevention of allergic disorders during infancy through immunosuppression. The patent discusses the increasing prevalence of allergies in Japan and other developed countries and the economic burden associated with treating allergic disorders. The method involves administering an anti-IgE antibody to pregnant mothers to suppress the production of allergen-specific IgE antibodies in their infants. The goal is to prevent the onset of allergic disorders in infancy and reduce the overall medical costs associated with treating allergies. [Extracted from the article]

A researcher at Rush University College of Nursing in Chicago has presented data on food allergies. The research highlights the need for accurate diagnosis, emergency treatment plans, and management options for patients with food allergies. The study reviews the pathophysiology of food allergies, current and emerging diagnostics, treatments, and emergency management. It also discusses promising new treatment options, including oral immunotherapy and immune-modulating biologic agents. The research concludes that there is hope for novel therapies to become viable options in the near future, reducing the reliance on strict avoidance as the only treatment plan. Nurse practitioners can support patients with food allergies by staying informed about research progress and helping them consider novel treatment options. [Extracted from the article]

A recent report from Deventer Hospital in the Netherlands discusses the rising prevalence of food allergies and the standard care practices of allergen avoidance and rescue medication. The report highlights the potential of oral immunotherapy (OIT) as a treatment option, particularly for children under the age of 4. Early OIT studies have shown promising outcomes in terms of sustained unresponsiveness (SU) and the prevention of persistent food allergies. The underlying mechanisms of the effectiveness of early OIT are not yet fully understood, but upcoming studies will provide more data on its safety and feasibility. [Extracted from the article]

A recent report from the Icahn School of Medicine at Mount Sinai discusses the use of epitope-specific IgE antibody profiling in diagnosing and predicting food allergies. Epitope-based testing detects IgE antibodies that directly bind to allergenic sites, providing more accurate results and fewer false positives. These profiles can also serve as prognostic markers for food allergies and help predict the severity of reactions and outcomes of treatment options. Further studies are being conducted to explore additional applications of epitope-specific antibodies for multiple food allergens. [Extracted from the article]

Researchers from DBV Technologies in Montrouge, France have published new findings on epicutaneous immunotherapy (EPIT) for the treatment of food allergies. EPIT is a promising approach that targets the skin to induce immune tolerance, reducing the risk of allergen passage into the bloodstream. The Viaskin patch, which contains dried allergen extracts, is the most clinically advanced EPIT approach. Preclinical and clinical studies have shown that EPIT can induce long-lasting T-regulatory cells and provide a non-invasive therapy with no restrictions on daily activities. This research supports further investigation into EPIT as a potential treatment option for allergic disorders. [Extracted from the article]

Keywords: Allergies; Drugs and Therapies; Epidemiology; Food Allergies; Gastroenterology; Health and Medicine; Immune System Diseases and Conditions; Immunology; Immunotherapy; Pulmonology EN Allergies Drugs and Therapies Epidemiology Food Allergies Gastroenterology Health and Medicine Immune System Diseases and Conditions Immunology Immunotherapy Pulmonology 1845 1845 1 09/25/23 20230925 NES 230925 2023 SEP 25 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Research findings on food allergies are discussed in a new report. Allergies, Drugs and Therapies, Epidemiology, Gastroenterology, Health and Medicine, Immune System Diseases and Conditions, Immunology, Immunotherapy, Pulmonology, Food Allergies. [Extracted from the article]

Keywords: Allergens; Allergic Rhinitis; Allergies; Allergy Research; Antigens; Asthma; Biomarkers; Bronchial Diseases and Conditions; Clinical Research; Clinical Trials and Studies; Diagnostics and Screening; Drugs and Therapies; Food Allergies; Genetics; Health and Medicine; Immune System Diseases and Conditions; Immunology; Immunotherapy; Lung Diseases and Conditions; Military Medicine; Military and Defense; Nose Diseases and Conditions; Obstructive Lung Diseases and Conditions; Otorhinolaryngologic Diseases and Conditions; Pediatrics; Respiratory Hypersensitivity; Respiratory Tract Diseases and Conditions; Respiratory Tract Infections; Rhinitis; Risk and Prevention EN Allergens Allergic Rhinitis Allergies Allergy Research Antigens Asthma Biomarkers Bronchial Diseases and Conditions Clinical Research Clinical Trials and Studies Diagnostics and Screening Drugs and Therapies Food Allergies Genetics Health and Medicine Immune System Diseases and Conditions Immunology Immunotherapy Lung Diseases and Conditions Military Medicine Military and Defense Nose Diseases and Conditions Obstructive Lung Diseases and Conditions Otorhinolaryngologic Diseases and Conditions Pediatrics Respiratory Hypersensitivity Respiratory Tract Diseases and Conditions Respiratory Tract Infections Rhinitis Risk and Prevention 498 498 1 09/19/23 20230919 NES 230919 2023 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Staff editors report on the newly launched clinical trial, NCT06021912, which has the following summary description: "Allergy is defined as a specific abnormal and excessive reaction of the immune system to exposed allergen. Patients with poorly controlled asthma despite optimal treatment Ineffective drug treatment Patients willing to adhere to our research protocol Exclusion Criteria: Patients with multi-allergenic asthma (more than 2 allergens) Pregnancy (at the time of ITA initiation). [Extracted from the article]

"In some embodiments, there is a tree nut flour composition comprising defatted tree nut flour, wherein at least 50% of the defatted tree nut flour by weight passes through a 250 m sieve. The method of claim 2, further comprising separating larger particles in the nut flour from smaller nut particles in the nut flour, and retaining the smaller nut particles. "In some embodiments of any of the methods described above, the method comprises separating larger particles in the nut flour from smaller nut particles in the nut flour, and retaining the smaller nut particles. "In some embodiments, the defatted tree nut flour is produced according to a method comprising contacting a tree nut material with a supercritical fluid; and milling the tree nut material to form the defatted tree nut flour. [Extracted from the article]

Our results demonstrate the molecular basis of antibody-mediated protection in IgE-mediated food allergy, by defining how these antibodies disrupt IgE-allergen interactions to prevent allergic reactions. Keywords: Boston; State:Massachusetts; United States; North and Central America; Allergens; Allergies; Allergy Research; Antibodies; Antigens; Blood Proteins; Drugs and Therapies; Epitopes; Food Allergies; Health and Medicine; Immune System Diseases and Conditions; Immunoglobulins; Immunology; Immunoproteins; Immunotherapy; Neutralizing Antibodies; Proteins; Serum Globulins EN Boston State:Massachusetts United States North and Central America Allergens Allergies Allergy Research Antibodies Antigens Blood Proteins Drugs and Therapies Epitopes Food Allergies Health and Medicine Immune System Diseases and Conditions Immunoglobulins Immunology Immunoproteins Immunotherapy Neutralizing Antibodies Proteins Serum Globulins 334 334 1 07/03/23 20230704 NES 230704 2023 JUL 7 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Immune System Diseases and Conditions - Allergies have been published. [Extracted from the article]

Keywords: Allergies; Asthma; Biomarkers; Blood Cells; Bronchial Diseases and Conditions; Cincinnati Children's Hospital Medical Center; Clinical Research; Clinical Trials and Studies; Diagnostics and Screening; Digestive System Diseases and Conditions; Drugs and Therapies; Dupilumab Therapy; Eosinophils; Food Allergies; Food Allergy; Gastritis; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Granulocytes; Health and Medicine; Hemic and Immune Systems; Immune System Diseases and Conditions; Immunologic Agents; Immunology; Immunotherapy; Inflammation; Lung Diseases and Conditions; Monoclonal Antibodies; Obstructive Lung Diseases and Conditions; Pharmaceuticals; Placebos; Respiratory Hypersensitivity; Respiratory Tract Diseases and Conditions; Stomach Diseases and Conditions EN Allergies Asthma Biomarkers Blood Cells Bronchial Diseases and Conditions Cincinnati Children's Hospital Medical Center Clinical Research Clinical Trials and Studies Diagnostics and Screening Digestive System Diseases and Conditions Drugs and Therapies Dupilumab Therapy Eosinophils Food Allergies Food Allergy Gastritis Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Granulocytes Health and Medicine Hemic and Immune Systems Immune System Diseases and Conditions Immunologic Agents Immunology Immunotherapy Inflammation Lung Diseases and Conditions Monoclonal Antibodies Obstructive Lung Diseases and Conditions Pharmaceuticals Placebos Respiratory Hypersensitivity Respiratory Tract Diseases and Conditions Stomach Diseases and Conditions 1428 1428 1 07/03/23 20230704 NES 230704 2023 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- The good news: a monoclonal antibody treatment called benralizumab proved quite effective in a clinical trial at depleting the number of eosinophils found in the blood and digestive tract tissues of patients with eosinophilic gastritis. [Extracted from the article]